Chad Gassert - ANI Pharmaceuticals Senior Strategy
| ANIP Stock | USD 64.35 0.52 0.80% |
Executive
Chad Gassert is Senior Strategy of ANI Pharmaceuticals
| Age | 48 |
| Address | 210 Main Street West, Baudette, MN, United States, 56623 |
| Phone | 218 634 3500 |
| Web | https://www.anipharmaceuticals.com |
Latest Insider Transactions
Chad Gassert Latest Insider Activity
Tracking and analyzing the buying and selling activities of Chad Gassert against ANI Pharmaceuticals stock is an integral part of due diligence when investing in ANI Pharmaceuticals. Chad Gassert insider activity provides valuable insight into whether ANI Pharmaceuticals is net buyers or sellers over its current business cycle. Note, ANI Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell ANI Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Chad Gassert over six months ago Disposition of 20000 shares by Chad Gassert of ANI Pharmaceuticals at 63.44 subject to Rule 16b-3 | ||
Chad Gassert over six months ago Disposition of 20000 shares by Chad Gassert of ANI Pharmaceuticals at 64.41 subject to Rule 16b-3 |
ANI Pharmaceuticals Management Efficiency
As of 03/21/2025, Return On Capital Employed is likely to grow to 0.0006, while Return On Tangible Assets are likely to drop (0.03). At this time, ANI Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 03/21/2025, Liabilities And Stockholders Equity is likely to grow to about 1.3 B, while Non Current Liabilities Other is likely to drop slightly above 16.1 M. ANI Pharmaceuticals' management efficiency ratios could be used to measure how well ANI Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dimitri Grigoriadis | Neurocrine Biosciences | 66 | |
| Rong MS | Amphastar P | 66 | |
| Christopher OBrien | Neurocrine Biosciences | 67 | |
| DO Ellis | Pacira BioSciences, | 53 | |
| Elizabeth Geary | Ironwood Pharmaceuticals | N/A | |
| Darin Esq | Neurocrine Biosciences | 59 | |
| Jana Noeldeke | Ironwood Pharmaceuticals | N/A | |
| Bart Dunn | Collegium Pharmaceutical | N/A | |
| Michael MD | Ironwood Pharmaceuticals | 66 | |
| Archana Bhaskar | Dr Reddys Laboratories | 53 | |
| Itai Kabiljo | INC Research Holdings | N/A | |
| Lauren Riker | Pacira BioSciences, | 46 | |
| Mike Nanfito | Ironwood Pharmaceuticals | N/A | |
| Carlos Russo | Procaps Group SA | 39 | |
| Susan Mesco | Pacira BioSciences, | N/A | |
| Krishna MS | Dr Reddys Laboratories | 52 | |
| Vivek Mittal | Dr Reddys Laboratories | N/A | |
| Kyle Gano | Neurocrine Biosciences | 52 | |
| Bhethanabottla Phanimitra | Dr Reddys Laboratories | N/A | |
| Dan MBA | Amphastar P | N/A | |
| Sandeep Poddar | Dr Reddys Laboratories | N/A | |
Management Performance
| Return On Equity | -0.0418 | ||||
| Return On Asset | 0.0084 |
ANI Pharmaceuticals Leadership Team
Elected by the shareholders, the ANI Pharmaceuticals' board of directors comprises two types of representatives: ANI Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ANI. The board's role is to monitor ANI Pharmaceuticals' management team and ensure that shareholders' interests are well served. ANI Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ANI Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elizabeth JD, Chief Disease | ||
| Stephen Carey, CFO, Vice President | ||
| Krista Davis, Senior Officer | ||
| Muthusamy RPh, COO RD | ||
| Thomas Rowland, Senior Brands | ||
| Nikhil Lalwani, CEO President | ||
| Meredith Cook, General VP | ||
| Chad Gassert, Senior Strategy | ||
| James Marken, Senior Development | ||
| Ori Gutwerg, Senior Generics | ||
| Meredith JD, General VP | ||
| Christopher Mutz, Senior Disease | ||
| Mary MD, Chief Officer |
ANI Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ANI Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0418 | ||||
| Return On Asset | 0.0084 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 1.91 B | ||||
| Shares Outstanding | 21.76 M | ||||
| Shares Owned By Insiders | 11.22 % | ||||
| Shares Owned By Institutions | 97.41 % | ||||
| Number Of Shares Shorted | 2.56 M | ||||
| Price To Earning | 43.35 X |
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.